Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avanos Medical (AVNS) Operating Leases (2019 - 2025)

Avanos Medical's Operating Leases history spans 6 years, with the latest figure at $26.5 million for Q3 2024.

  • For Q3 2024, Operating Leases fell 10.17% year-over-year to $26.5 million; the TTM value through Sep 2024 reached $26.5 million, down 10.17%, while the annual FY2023 figure was $28.3 million, 36.4% down from the prior year.
  • Operating Leases for Q3 2024 was $26.5 million at Avanos Medical, down from $28.8 million in the prior quarter.
  • Across five years, Operating Leases topped out at $58.9 million in Q2 2020 and bottomed at $26.5 million in Q3 2024.
  • The 5-year median for Operating Leases is $40.0 million (2022), against an average of $40.9 million.
  • The largest annual shift saw Operating Leases rose 3.97% in 2022 before it tumbled 36.4% in 2023.
  • A 5-year view of Operating Leases shows it stood at $53.3 million in 2020, then fell by 19.7% to $42.8 million in 2021, then grew by 3.97% to $44.5 million in 2022, then crashed by 36.4% to $28.3 million in 2023, then fell by 6.36% to $26.5 million in 2024.
  • Per Business Quant, the three most recent readings for AVNS's Operating Leases are $26.5 million (Q3 2024), $28.8 million (Q2 2024), and $26.6 million (Q1 2024).